Canadian Cardiovascular Society Receives $1.6 million to Study Myocarditis and/or Pericarditis after mRNA COVID-19 Vaccination
OTTAWA, ON, Oct. 27, 2022 /CNW/ – Today, at the Canadian Cardiovascular Congress where more than 1200 cardiovascular specialists and allied health professionals have gathered, Dr. Howard Njoo, Canada’s Deputy Chief Public Health Officer and Interim Vice-President of the Infectious Diseases Programs Branch, announced funding to support a pan-Canadian study of the clinical and functional outcomes of adults and children who experienced myocarditis and/or pericarditis after receiving an mRNA COVID-19 vaccination.
The Canadian Cardiovascular Society (CCS) will receive $1,6 million from the Government of Canada to conduct the study. As a national organization representing more than 2300 cardiologists, cardiac surgeons and other heart health specialists across the country, and with a broad network, the CCS is well positioned to lead this initiative.
“Myocarditis and pericarditis occur rarely following mRNA COVID-19 vaccination,” says Dr. Nathaniel Hawkins, Centre for Cardiovascular Innovation at the University of British Columbia and the project’s scientific lead. “Most people recover quickly and well, but the long-term health effects of these heart conditions are unknown.”
